Evidence map›Paper›PMID 34865649›Full record

ArticleBMC complementary medicine and therapies2021

Hericium erinaceus mycelium ameliorate anxiety induced by continuous sleep disturbance in vivo.

Tsung-Ju Li, Tung-Yen Lee, Yun Lo, Li-Ya Lee, I-Chen Li, Chin-Chu Chen, Fang-Chia Chang

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Antioxidants, Hormetic Nutrition, and Autism.Current neuropharmacology · 2024
    Review
  7. Lion's Mane (Behavioral sciences (Basel, Switzerland) · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tsung-Ju LiBiotech Research Institute, Grape King Bio, Taoyuan, 32542, Taiwan.
Tung-Yen LeeDepartment of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
Yun LoDepartment of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
Li-Ya LeeBiotech Research Institute, Grape King Bio, Taoyuan, 32542, Taiwan.
I-Chen LiBiotech Research Institute, Grape King Bio, Taoyuan, 32542, Taiwan.
Chin-Chu ChenBiotech Research Institute, Grape King Bio, Taoyuan, 32542, Taiwan. gkbioeng@grapeking.com.tw.
Fang-Chia ChangDepartment of Veterinary Medicine, National Taiwan University, Taipei, Taiwan. fchang@ntu.edu.tw.
National Taiwan University · TWGenMont Biotech (Taiwan) · TWGrape King (Taiwan) · TWShih Chien University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSleep disruption is a major public health issue and may increase the risk of mortality by ten-folds if an individual is sleeping less than 6 h per night. Sleep has changed dramatically during to the COVID-19 pandemic because COVID symptoms can lead to psychological distress including anxiety. Hericium erinaceus mycelium has been widely investigated in both the in vivo studies and clinical trials for its neuroprotective functions because the mycelium contains hericenones and erinacines, which synthesize the nerve growth factor and brain-derived neurotrophic factor (BDNF). Recent in vivo reports have shown showed that erinacine A-enriched Hericium erinaceus mycelium can modulate BDNF/TrkB/PI3K/Akt/GSK-3β pathways to induce an antidepressant-like effect. A large body of evidence indicates that erinacine can pass the blood-brain barrier and suggests its neuroprotective function in both peripheral and central nervous systems. Thus, Hericium erinaceus mycelium may be a dual-function supplement for sleep disruption improvement while sustaining anxiolytic effects.

methodTo simulate the condition of sleep disruption, the mice were subjected to the tail suspension test (TST) for 15 min every day during the same period for nine consecutive days. Two different doses (75 and 150 mg/kg) of Hericium erinaceus mycelium were administered orally 20 min prior to the TSTs before entering the light period of 12:12 h L:D cycle. All sleep-wake recording was recorded for 24 h using electroencephalogram and electromyogram. The elevated-plus-maze and open-field tests were conducted to record the behavior activities.

resultsConsecutive TSTs prior to the light period could cause significant sleep disturbance and anxiety behavior in the elevated-plus-maze experiments. Results showed that administration with Hericium erinaceus mycelium at 150 mg/kg ameliorated the rodent anxiety (p < 0.05) and reversed the TST-induced NREM sleep disturbance in the dark period.

conclusionThis is the first in vivo study suggesting that Hericium erinaceus mycelium has a dual potential role for anxiety relief through improving sleep disruptions.

Indexed as

HericiumMyceliumAnimalsAnxietyBiological ProductsCOVID-19Disease Models, AnimalMiceMice, Inbred C57BLSleepSleep Wake DisordersBiological ProductsAnxietyCOVID-19Hericium erinaceus myceliumNREMSleep

Identifiers

PMID34865649
PMCPMC8643634
OpenAlexW4200226894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.